- Home
- AVTX vs NRSN Comparison
AVTX vs NRSN Comparison
Compare AVTX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- NRSN
- Stock Information
- Founded
- AVTX 2011
- NRSN 2017
- Country
- AVTX United States
- NRSN Israel
- Employees
- AVTX N/A
- NRSN N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- NRSN Health Care
- Exchange
- AVTX Nasdaq
- NRSN Nasdaq
- Market Cap
- AVTX 57.4M
- NRSN 50.1M
- IPO Year
- AVTX 2015
- NRSN 2021
- Fundamental
- Price
- AVTX $7.89
- NRSN $1.08
- Analyst Decision
- AVTX Strong Buy
- NRSN Buy
- Analyst Count
- AVTX 7
- NRSN 2
- Target Price
- AVTX $31.00
- NRSN $14.00
- AVG Volume (30 Days)
- AVTX 149.3K
- NRSN 315.6K
- Earning Date
- AVTX 08-11-2025
- NRSN 09-29-2025
- Dividend Yield
- AVTX N/A
- NRSN N/A
- EPS Growth
- AVTX N/A
- NRSN N/A
- EPS
- AVTX N/A
- NRSN N/A
- Revenue
- AVTX $441,000.00
- NRSN N/A
- Revenue This Year
- AVTX N/A
- NRSN N/A
- Revenue Next Year
- AVTX N/A
- NRSN N/A
- P/E Ratio
- AVTX $1.17
- NRSN N/A
- Revenue Growth
- AVTX N/A
- NRSN N/A
- 52 Week Low
- AVTX $3.39
- NRSN $0.60
- 52 Week High
- AVTX $16.00
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- AVTX 80.64
- NRSN 22.62
- Support Level
- AVTX $6.21
- NRSN $1.69
- Resistance Level
- AVTX $6.89
- NRSN $2.09
- Average True Range (ATR)
- AVTX 0.64
- NRSN 0.19
- MACD
- AVTX 0.17
- NRSN -0.08
- Stochastic Oscillator
- AVTX 78.59
- NRSN 7.27
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.